On July 1, 2025, Teleflex, a prominent medical technology leader, completed the acquisition of substantially all of BIOTRONIK’s Vascular Intervention business for approximately €760 million, or about $823 million.
This acquisition significantly expands Teleflex’s portfolio with a diverse range of therapeutic products for coronary and peripheral interventions. New additions include the Pantera™ Lux™ Drug-Coated Balloon Catheter, PK Papyrus™ Covered Coronary Stent, Orsiro™ Mission Drug Eluting Stent, and Freesolve™ Resorbable Metallic Scaffold (RMS) technology.
The strategic goal of this move is to strengthen Teleflex’s interventional device offerings, increase its global presence in catheterization laboratories, gain a stronger foothold in the rapidly expanding peripheral intervention market, and strengthen its innovation pipeline, particularly in the promising field of resorbable scaffold technologies.
The financial projections for this acquisition are favorable, with an expected revenue contribution of €177 million ($204 million) in the second half of 2025, followed by 6% or higher annual constant currency revenue growth beginning in 2026. The transaction is also expected to add approximately $0.10 to Teleflex’s adjusted earnings per share in the first year of ownership, with continued accretion thereafter. This acquisition puts Teleflex at the forefront of the changing trend in vascular interventions toward solutions that require less permanent hardware.
A powerful addition to Teleflex’s arsenal.
The acquisition adds a wealth of cutting-edge therapeutic products to the Teleflex portfolio, addressing critical needs in catheterization laboratories around the world. Notable additions include:
- The Pantera™ Lux™ Drug-Coated Balloon Catheter is a highly regarded treatment for coronary artery disease.
- The PK Papyrus™ Covered Coronary Stent is a new life-saving device for acute coronary artery perforation.
- The Orsiro™ Mission Drug Eluting Stent is an ultrathin stent with proven clinical effectiveness.
- Freesolve™ Resorbable Metallic Scaffold (RMS) Technology: A true game changer that fits into the growing trend of “leave behind less permanent hardware” solutions.
- Strategic Vision: Empowering Interventional Care.
- Improving interventional device offerings: Teleflex’s expanded product line positions it as a more comprehensive player in the interventional space, providing solutions for a broader range of procedures.
- Increasing Global Presence in the Cath Lab: The acquisition expands Teleflex’s presence in catheterization laboratories worldwide, leveraging BIOTRONIK’s established global presence and customer relationships.
- Gaining a stronger foothold in peripheral interventions: The peripheral intervention market is rapidly expanding, and this acquisition provides Teleflex with immediate scale and advanced technologies to capitalize on that growth.
- Reinforcing the Innovation Pipeline. The deal gives Teleflex access to BIOTRONIK’s R&D capabilities, including the Freesolve™ Resorbable Metallic Scaffold technology. Teleflex plans to expand clinical trials for Freesolve™, including a pivotal study in the United States.
The promise of resorbable scaffolds: A paradigm shift
The integration of Freesolve™ RMS technology is especially exciting. This novel approach aims to provide temporary scaffolding and drug delivery to a vessel, which will then gradually resorb, leaving a naturally healed artery free of permanent metallic implants. This “leave nothing behind” philosophy is a significant trend in vascular interventions, with the potential to provide long-term benefits to patients by reducing the risks associated with permanent hardware, such as chronic inflammation, late-stage thrombosis, and future reinterventions. Clinical studies for Freesolve™ (DREAMS-3G) have shown promising results, demonstrating complete resorption within 12 months and favorable safety and efficacy profiles.
A favorable financial outlook
The financial projections for this acquisition are similarly compelling. Teleflex expects the acquired business to generate a significant €177 million ($204 million) in revenue in the second half of 2025. Looking ahead, the annual constant currency revenue growth rate is expected to be 6% or higher beginning in 2026. Furthermore, the transaction is expected to add approximately $0.10 to Teleflex’s adjusted earnings per share in the first year of ownership, with increasing accretion in subsequent years, highlighting the immediate and long-term financial benefits of this strategic move.
What Does This Mean for the Future
Teleflex’s acquisition of BIOTRONIK’s Vascular Intervention business is more than a transaction; it is a bold statement of intent. Teleflex is positioned at the forefront of the evolving vascular intervention market by combining a highly complementary portfolio of therapeutic products and investing in cutting-edge resorbable scaffold technologies. This move promises improved patient care through innovative solutions, a larger global footprint, and a robust innovation pipeline that will undoubtedly shape the future of minimally invasive cardiovascular procedures for many years to come.
